UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

~~November~~March 185, ~~2013~~ 2015

Assured Pharmacy, Inc.
(Exact name of registrant as specified in its charter)

Nevada	001-35735	98-0233878
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

5600 Tennyson Parkway, Suite 390, Plano, Texas 75024

(Address of principal executive offices)

(972) 473-4033

Registrant's telephone number, including area code

___________________________________________________
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 51.0701 Entry -Into ~~Submission of Matters to~~ a ~~Vote~~Material ofDefinitive ~~Security Holders~~Agreement.

~~Assured~~In ~~Pharmacy,~~conjunction ~~Inc.~~with the filing of the Chapter 11 Cases (defined below), the “Company has executed an Equity Purchase Agreement with Precise Analytical, LLC, a private Delaware limited liability company (“Precise”), ~~submitted~~ the ~~following~~effectiveness ~~actions~~of which is subject to bethe ~~taken~~entry byof ~~consent~~a Confirmation Order of ~~its~~the ~~shareholders~~Bankruptcy inCourt ~~lieu~~approving the Debtors’ proposed plan of reorganization. The proposed plan and a ~~meeting~~proposed indisclosure ~~its~~statement ~~definitive~~were ~~proxy~~filed with the bankruptcy petitions, and the Debtors have asked for expedited consideration of the disclosure statement. Upon the effective date of the bankruptcy plan, if approved by the Bankruptcy Court, Precise shall receive 100% of the shares of the reorganized Company’s common stock for a purchase price to be calculated based on a base purchase price of $11,500,000 with deductions from the purchase price for the Company’s debt outstanding under the DIP Facility (as ~~filed~~defined in the Equity Purchase Agreement) and the amount, if any, by which the Target Working Capital exceeds the Closing Working Capital (such terms are defined in the Equity Purchase Agreement) and with an addition to the Upurchase price for the amount, if any, by which the Closing Working Capital exceeds the Target Working Capital.S. ~~Securities~~Upon payment of the purchase price, the Company will contribute the proceeds to the Plan Escrow and ~~Exchange~~the ~~Commission~~Professional onFee ~~October~~Escrow. 29Additional adjustments to the purchase price may be made within 90 days after the closing date, ~~2013~~depending on the Company’s balance sheets (including the ~~“Proxy~~subsidiaries’ ~~Statement”~~balance sheets): and the actual amounts of the Closing Working Capital, cash and the amounts paid in cash pursuant to the plan. The proceeds in the Plan Escrow will then be distributed to pay creditors and certain interest holders pursuant to the plan.

Item 1.03 Bankruptcy ~~Amend~~or ~~and restate the Articles of Incorporation of the Company to increase the authorized number of shares of Common Stock available for issuance from 35,000,000 to 100,000,000~~Receivership.

2On March 5, 2015 (“Petition Date”), Assured Pharmacy, Inc. ~~Create~~(the “Company”) and ~~designate~~its asubsidiaries ~~class~~Assured ofPharmacy ~~Preferred~~Management, ~~Stock~~Inc., ~~called~~Assured Pharmacy Dallas, Inc., Assured Pharmacy Boston, Inc., Assured Pharmacy Denver, Inc., Assured Pharmacies, Inc., Assured Pharmacy Gresham, Inc., Assured Pharmacy Kansas, Inc., Assured Pharmacies Northwest, Inc., and CS Compliance Group, Inc., (collectively, the “~~Series~~Debtors”) Dfiled ~~Preferred~~voluntary ~~Stock,~~petitions in the United States Bankruptcy Court for the Eastern District of Texas (the “Bankruptcy Court”) ~~consisting~~for reorganization relief under the provisions of ~~15,000~~Chapter ~~shares~~11 of ~~stock,~~Title ~~par~~11 ~~value~~of $0the United States Code (the “Bankruptcy Code”).~~001~~ ~~per~~The ~~share,~~Company has requested that the Chapter 11 cases be jointly administered and ~~designate~~styled as In re Assured Pharmacy, Inc., et al., Case No. 15-40389 (the “Chapter 11 Cases”). The Debtors will continue to ~~such~~operate ~~class~~their ofbusinesses ~~stock~~and ~~those~~manage ~~rights~~their properties as ~~described~~debtors in ~~that~~possession ~~certain~~under ~~Certificate~~the jurisdiction of ~~Designation~~the ~~attached~~Bankruptcy asCourt ~~Exhibit~~and Bin toaccordance with the ~~Company’s~~applicable ~~Proxy~~provisions ~~Statement~~of the Bankruptcy Code and orders of the Bankruptcy Court.

~~Voting~~The ~~closed~~proposed onplan ~~November~~and ~~18,~~disclosure ~~2013,~~statement atand ~~which~~the ~~time~~other ~~both~~documents ~~proposals~~filed ~~were~~in ~~approved~~connection bywith anthe ~~affirmative~~bankruptcy ~~vote~~modify ofand asupplement ~~majority~~all of the ~~outstanding~~descriptions ~~shares~~contained ofherein, ~~the~~and ~~Company’s~~control ~~common~~over ~~and~~any ~~preferred~~contrary ~~stock~~statements ~~entitled~~herein. toThe ~~vote~~plan ~~thereon~~is subject to change. AsNeither ~~indicated~~the inplan nor the ~~Proxy~~disclosure ~~Statement~~statement have been approved at this time, and the ~~Company~~descriptions ~~determined~~herein ~~October~~are 8,not ~~2013~~intended to be ~~the~~and ~~record~~shall ~~date~~not be treated as a solicitation of support for the ~~determination~~plan. ofThe ~~shareholders~~bankruptcy ~~entitled~~filings toincluding ~~notice~~the ~~of,~~plan and todisclosure ~~vote~~statement ~~upon,~~are publicly available on the ~~proposals.~~PACER ~~With~~system ~~respect~~used by the Bankruptcy Court to ~~each~~allow ~~action~~public ~~submitted~~access to ~~shareholder~~filed ~~vote~~documents, described more fully in the ~~shareholders~~Bankruptcy ~~voted~~Court aswebsite ~~set~~listed ~~forth~~in ~~below~~Item 7.01.

~~Action~~Item 1:2.04 Triggering AsEvents toThat ~~the~~Accelerate ~~increase~~or inIncrease ~~the~~a ~~number~~Direct ofFinancial ~~shares~~Obligation ofor ~~Common~~an ~~Stock~~Obligation ~~available~~under ~~for~~an ~~issuance~~Off-Balance ~~from~~Sheet ~~35,000,000 to 100,000,000, the voting results were as follows:~~Arrangement.

Number of Votes For:		Number of Votes Against:
9,629,829		496,897

The commencement of the Chapter 11 Cases described in Item 1.03 above constitutes an event of default under the agreements listed on Exhibit 99.2. This exhibit is not an exhaustive list of creditors nor is it an exhaustive list of all agreements in which Company is in default; it only lists such agreements that are in default as a result of the filing of the Chapter 11 Cases.

~~Action 2:~~ As toof the ~~creation~~Petition ~~and~~Date, ~~designation~~there ofwas a ~~class~~total of ~~Preferred~~$3,443,166 ~~Stock~~in ~~called~~principal payable under the ~~“Series~~agreements Dlisted ~~Preferred~~on ~~Stock~~Exhibit 99.1. Nothing in the listing of creditors on Exhibit 99.1 is an acknowledgment that the debts listed will be allowed,” or waives any rights, if any, of the ~~voting~~Debtors ~~results~~to ~~were~~contest asthem ~~follows:~~on any basis allowed by law.

Number of Votes For:		Number of Votes Against:
9,629,829		496,897

As a result of the filing of Chapter 11 Case, the Company believes that the ability of the lenders/creditors to seek remedies to enforce their rights against the Company under these and other agreements are stayed and creditor rights of enforcement against the Debtors are subject to the applicable provisions of the Bankruptcy Code.

Item 7.01 Regulation FD Disclosure.

Additional Information on the Chapter 11 Cases can be found on: https://www.txeb.uscourts.gov

The information in Item 7.01 of this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing.

Cautionary Statements Regarding the Chapter 11 Cases

The Company’s security holders are cautioned that trading in the Company’s securities during the pendency of the Chapter 11 Cases will be highly speculative and will pose substantial risks. If the plan is confirmed and closing occurs on the Equity Purchase Agreement, the existing common stock will be canceled. It is not anticipated that the holders of the common stock will receive any distributions under the plan. For example, if the plan is confirmed and closing occurs on the Equity Purchase Agreement, the existing common stock and any other equity interests, warrants and options will be canceled. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders thereof in the Company’s Chapter 11 Cases. Accordingly, the Company urges extreme caution with respect to existing and future investments in its securities.

Holders of the Company’s common stock, warrants or options are not expected to have any recovery in the Chapter 11 Cases.

Item 9.01 Financial Statements and Exhibits

Exhibit Number		Decription

Exhibit 1.1		Equity Purchase Agreement by and between Assured Pharmacy, Inc. and Precise Analytical, LLC

Exhibit 99.1		Table of Direct Financial Obligations Accelerated or Increased as a Result of the Chapter 11 Cases

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: ~~November~~ March 209, ~~2013~~2015

ASSURED PHARMACY, INC., a Nevada corporation

By:	/s/ Robert DelVecchio
Name:	Robert DelVecchio
Title:	Chief Executive Officer

- 2 -

Filing Compare · ASSURED PHARMACY, INC.